<DOC>
	<DOCNO>NCT00301392</DOCNO>
	<brief_summary>The purpose study evaluate effect pitavastatin prevent diabetes population impair glucose tolerance .</brief_summary>
	<brief_title>Japan Prevention Trial Diabetes Pitavastatin Patients With Impaired Glucose Tolerance ( J-PREDICT )</brief_title>
	<detailed_description>Diabetes mellitus complication major health problem globally . People impair glucose tolerance ( IGT ) high risk develop diabetes . It therefore important focus prevent diabetes individual IGT . HMG-CoA reductase inhibitor ( statin ) widely use hypercholesterolemia , one frequent metabolic disorder . However , direct evidence whether statin beneficial prevent diabetes . This study design compare efficacy life-style modification versus life-style modification pitavastatin ( statin ) administration , individual IGT .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>Inclusion Criteria screen test ( within 6 month screen ) : LDLcholesterol 100159 mg/dl and/or total cholesterol 180239 mg/dl At least one following : 1 . Fasting plasma glucose 100125 mg/dl , and/or casual ( nonfasting ) plasma glucose 120199 mg/dl , and/or HbA1c 5.56.0 % 2 . At least two follow risk factor impair glucose tolerance : 1 . Second degree relative diabetes 2 . BMI &gt; = 24 kg/m2 3 . Systolic blood pressure &gt; =130 mmHg , and/or diastolic blood pressure &gt; = 85 mmHg , and/or receive treatment hypertension 4 . Triglyceride &gt; = 150 mg/dl , and/or HDL &lt; 40 mg/dl Written consent participation study volition provide sufficient explanation participation clinical trial Inclusion Criteria entry ( Confirmed screen test ) : Impaired glucose tolerance 75g oral glucose tolerance test ( fast plasma glucose &lt; 126 mg/dl 2h plasma glucose 140199 mg/dl ) History diabetes ( except gestational diabetes ) Fasting plasma glucose &gt; = 126 mg/dl , and/or 2h plasma glucose &gt; = 200 mg/dl HbA1c &gt; = 6.5 % Diabetic retinopathy Receiving hormone replacement therapy Pancreatic disease ( e.g . pancreatitis , pancreatectomy , pancreatic cancer ) , Endocrine diseases ( e.g . Cushing 's syndrome , acromegaly , pheochromocytoma , aldosteronism , hyperthyroidism ) Receiving statin , fibrates anion exchange resin Cancer suspect cancer History gastrectomy History myocardial infarction , angina , heart failure ( NYHA Class &gt; = III ) Severe hypertension ( SBP &gt; = 180 mmHg DBP &gt; = 110 mmHg ) Renal disease , include serum creatinine &gt; = 2.0 mg/dl Hepatic disease , include transaminase ( ALT AST ) &gt; = 2 time upper limit normal Women hop become pregnant intend study period Contraindication relative contraindication LivaloÂ® Tab ( pitavastatin calcium ) 1 . History hypersensitivity ingredient product 2 . Severe hepatic disorder biliary atresia 3 . Receiving cyclosporine 4 . Pregnant woman , woman suspect pregnant , lactate woman 5 . Patients receive fibrates also laboratory evidence abnormal renal function Familial hypercholesterolemia Drug abuse , alcoholism Individuals ineligible opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Glucose intolerance</keyword>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Statins , HMG-CoA</keyword>
</DOC>